Can Childhood be Used as a Model to Understand the Effects of Psychedelics?
Ethan Hurwitz, Jon G Dean, Caren M. Walker
Topics in Cognitive Science May 26, 2026 DOI: 10.1111/tops.70058 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Pilot study Qualitative Peer reviewed |
|---|---|
| Key points | Argues that psychedelics may enhance cognitive flexibility through mechanisms analogous to developmental changes seen in children, and proposes three testable behavioral indicators: altering reliance on priors, search and sampling strategies, and attentional allocation. Preliminary pilot data support this framework. |
Abstract
Psychedelic drugs have shown promise as a novel therapeutic for a variety of health conditions, yet the mechanisms underlying their clinical benefits remain unclear. A leading hypothesis suggests that psychedelics may enhance cognitive flexibility, a trait impaired in many of these conditions. While existing data from self-report and qualitative-interview studies support this hypothesis, data from experimental studies are limited and inconsistent. Here, we propose a novel cognitive development model that allows us to more precisely define cognitive flexibility as a mechanism underlying the effects of psychedelics. Considering children-a population known to be more cognitively flexible than adults-as a proxy psychedelic group, we identify three specific behaviors that could be used to empirically test this account: (1) changing the strength of, or reliance on, one's priors; (2) changing one's search and sampling strategies; and/or (3) changing one's allocation of attentional resources. Finally, we highlight preliminary findings from a pilot study supporting this framework and providing guidance for future work.
Citations in the library
Cites 50
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 45 more in the library